Welcome to our dedicated page for Hinge Health SEC filings (Ticker: HNGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hinge Health, Inc.'s SEC filings document its public-company reporting as an emerging growth company operating a technology platform for musculoskeletal care. Its Form 8-K filings cover quarterly and annual financial results, furnished earnings releases, supplemental investor materials, non-GAAP financial measures and reconciliations, and Regulation FD disclosures.
The company’s filings also record governance and capital-structure matters, including proxy materials for director elections and auditor ratification, board appointments and committee assignments, share repurchase authorization, Class A common stock disclosures, and post-IPO lock-up matters. These documents provide formal disclosure on operating results, stockholder voting matters, board oversight, capital allocation and securities-related events.
Hinge Health, Inc. CEO, Co‑Founder, director and 10% owner reported insider transactions dated December 15, 2025. On that date, he converted 166,670 shares of Class B common stock into Class A common stock at an exercise price of $0, then disposed of the same 166,670 Class A shares in open‑market sales.
The first sale covered 161,250 Class A shares at a weighted average price of $48.5031, within a range of $47.98 to $48.96. The second sale covered 5,420 shares at a weighted average price of $49.2962, within a range of $49.00 to $49.58. All sales were made under a Rule 10b5‑1 trading plan adopted on September 11, 2025.
After these transactions, he beneficially owned 14,543,427 shares of Class B common stock directly, plus 515,705 Class B shares and 35,470 Class A shares indirectly through his spouse.
A shareholder of the issuer filed a notice to sell 166,670 shares of common stock. The shares are planned to be sold through Morgan Stanley Smith Barney LLC on or about 12/15/2025 on the NYSE, with an aggregate market value listed as 8,283,499.00.
The securities were acquired on 03/22/2023 as restricted stock awards directly from the issuer, and the filing notes that 37,919,155 common shares were outstanding. By signing the notice, the seller represents that they are not aware of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.
Hinge Health, Inc. has an ownership report showing that Jane Street Group, LLC and related entities report beneficial ownership of 2,130,181 Class A common shares, representing 5.6% of the outstanding class as of 12/08/2025.
The shares are reported with no sole voting or dispositive power and shared voting and dispositive power over 2,130,181 shares. The report covers Jane Street Group, LLC together with Jane Street Capital, LLC, Jane Street Options, LLC, and Jane Street Global Trading, LLC. The certification states that the securities were not acquired and are not held for the purpose of changing or influencing the control of Hinge Health.
Hinge Health, Inc. Chief Financial Officer James Budge reported a change in his holdings of the company’s Class A common stock. On 12/11/2025, he disposed of 20,000 shares at a reported price of $0 under transaction code G, leaving him with 451,665 shares of Class A common stock held directly after the transaction. This filing was made as a Form 4 by a single reporting person.
Hinge Health, Inc. reported an insider transaction by a person who is a director, CEO, co‑founder and 10% owner. On 12/10/2025, the insider converted 11,680 shares of Class B Common Stock into 11,680 shares of Class A Common Stock at a stated price of $0 per share. On 12/12/2025, those 11,680 Class A shares were transferred as a gift, leaving the insider with 0 directly held Class A shares.
Following these transactions, the insider reported 14,710,097 derivative securities related to Class B Common Stock held directly, and an additional 515,705 derivative securities and 35,470 Class A shares held indirectly through a spouse. Each share of Class B Common Stock is convertible into one share of Class A Common Stock under conditions described in the company’s charter.
Hinge Health, Inc. reported an insider-related share sale involving a major shareholder. A director and 10% owner filed to report sales made by affiliated Bessemer venture funds on December 5, 2025. Bessemer Venture Partners X L.P. sold 2,614 shares of Class A common stock and Bessemer Venture Partners X Institutional L.P. sold 2,453 shares at a weighted average price of $50.0166, in multiple trades between $50.00 and $50.12. The reporting person is a partner at Bessemer Venture Partners and describes only an indirect, passive economic interest in these fund-held shares, formally disclaiming beneficial ownership beyond any pecuniary interest.
Bessemer Venture Partners affiliates filed a Form 144 indicating planned sales of HNGE Class A shares. The notice covers 2,453 Class A shares to be sold through Merrill Lynch, with an aggregate market value of $122,453.76 and 37,919,155 Class A shares outstanding as context. The approximate sale date is listed as December 5, 2025 on the NYSE.
The securities to be sold were acquired in a private placement from the issuer on February 4, 2020 and paid for in cash. The filing also reports multiple prior Class A sales during November 2025 by Bessemer Venture Partners X LP and Bessemer Venture Partners X Institutional LP, including blocks of 373,955 and 351,045 shares, each generating multi‑million dollar gross proceeds.
HNGE shareholders filed a Form 144 indicating an intent to sell 2,614 Class A shares through Merrill Lynch on the NYSE. The planned sale has an aggregate market value of 130,490.88, with Class A shares outstanding reported at 37,919,155. These shares were originally acquired from the issuer in a private placement on 02/04/2020 and paid for in cash on the same date.
Over the past three months, affiliated holders have already sold several large Class A blocks. Bessemer Venture Partners X LP reported sales including 373,955 shares on 11/18/2025 for gross proceeds of 14,976,898, 103,160 shares on 11/26/2025 for 4,979,533.2, and 23,176 shares on 11/28/2025 for 1,162,403.87. Bessemer Venture Partners X Institutional LP reported sales including 351,045 shares on 11/18/2025 for 14,059,352, 96,840 shares on 11/26/2025 for 4,674,466.8, and 21,757 shares on 11/28/2025 for 1,091,233.21.
Insight Venture Partners affiliates, identified as a director and 10% owner of Hinge Health, Inc. (HNGE), reported on Form 4 that on December 1, 2025 they converted multiple blocks of Class B Common Stock into Class A Common Stock and then sold those Class A shares.
The reporting persons converted and sold 826,216, 19,659, 677,508 and 131,057 shares of Class B/Class A stock, respectively, through affiliated Insight investment funds, with each corresponding Class A position shown as reduced to zero following the sales at a reported price of $47.76 per share.
Footnotes describe that each share of Class B Common Stock was convertible into one share of Class A Common Stock and outline Insight’s fund and holding-company structure, noting that various Insight entities and managers may be deemed to share voting and dispositive power over these Hinge Health shares while generally disclaiming beneficial ownership beyond their pecuniary interests.
HNGE filed a notice under Rule 144 for a proposed sale of restricted or control securities. The filing covers the planned sale of 19,659 shares of Class A stock through broker Merrill Lynch, with an aggregate market value of 961,521.69. These shares are part of a larger base of 37,919,155 shares outstanding and are expected to be sold on the NYSE on or about 12/01/2025. The seller originally acquired the 19,659 Class A shares from the issuer in a private placement on 07/03/2018, paying cash at that time.